FDA clears Tempus ECG-AF for a defined risk-notification use

FDA cleared Tempus ECG-AF to analyze eligible patients’ resting 12-lead ECGs for signs associated with atrial fibrillation or flutter within twelve months. The device supports further referral and follow-up; its labeling does not authorize directing treatment from the output.